Research Analysts’ Weekly Ratings Updates for Axon Enterprise (AXON)

Axon Enterprise (NASDAQ: AXON) has recently received a number of price target changes and ratings updates:

• 3/10/2025 – Axon Enterprise had its “hold” rating reaffirmed by analysts at Barclays PLC.
• 3/10/2025 – Axon Enterprise was downgraded by analysts at Craig Hallum from a “buy” rating to a “cautious” rating.
• 2/27/2025 – Axon Enterprise was given a new $726.00 price target on by analysts at Barclays PLC. They now have an “overweight” rating on the stock.
• 2/26/2025 – Axon Enterprise had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $600.00 price target on the stock.
• 2/20/2025 – Axon Enterprise was downgraded by analysts at Craig Hallum from a “buy” rating to a “hold” rating. They now have a $625.00 price target on the stock.
• 2/19/2025 – Axon Enterprise was downgraded by analysts at Northcoast Research from a “buy” rating to a “neutral” rating.
• 2/4/2025 – Axon Enterprise had its “outperform” rating reaffirmed by analysts at JMP Securities.
• 2/4/2025 – Axon Enterprise had its price target raised by analysts at JMP Securities from $610.00 to $725.00. They now have a “market outperform” rating on the stock.
• 1/27/2025 – Axon Enterprise had its price target raised by analysts at The Goldman Sachs Group, Inc. from $500.00 to $700.00. They now have a “buy” rating on the stock.

Axon Enterprise Stock Down 0.3 %

Axon Enterprise stock opened at $554.82 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm has a market capitalization of $42.51 billion, a price-to-earnings ratio of 143.36, a price-to-earnings-growth ratio of 5.17 and a beta of 1.12. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $715.99. The stock’s fifty day moving average is $593.10 and its two-hundred day moving average is $538.04.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey C. Kunins sold 1,035 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $624.47, for a total value of $646,326.45. Following the completion of the sale, the insider now directly owns 124,243 shares in the company, valued at $77,586,026.21. This trade represents a 0.83 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Axon Enterprise

Institutional investors and hedge funds have recently made changes to their positions in the stock. Public Sector Pension Investment Board lifted its position in shares of Axon Enterprise by 19.2% in the third quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock valued at $1,240,000 after acquiring an additional 500 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Axon Enterprise by 9.2% in the third quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock valued at $4,227,000 after acquiring an additional 895 shares in the last quarter. Soros Capital Management LLC purchased a new stake in shares of Axon Enterprise in the third quarter valued at $630,000. Friedenthal Financial lifted its position in shares of Axon Enterprise by 961.7% in the fourth quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock valued at $808,000 after acquiring an additional 1,231 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Axon Enterprise by 33.1% in the third quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company’s stock valued at $54,466,000 after acquiring an additional 33,869 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.